SCHEMBL1765843

SCHEMBL1765843

Cc1cc(C(=O)CCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C(C)C)ccc1CCC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 14/20 0.59
PPARA Q07869 10/20 0.59
PPARG P37231 9/20 0.59
FFAR1 O14842 5/20 0.47
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41
CRHBP P24387 1/20 0.41
KMT2A Q03164 1/20 0.41
CRHR2 Q13324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12938302 0.92 PPARD (0.49) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL30004371 0.92 PPARD (0.49) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL24658514 0.92 PPARD (0.49) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL4331755 0.91 PPARD (0.57) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL4327859 0.91 PPARD (0.50) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL4324880 0.91 PPARD (0.50) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL30003652 0.90 PPARD (0.47) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL12732568 0.90 PPARD (0.45) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL1765992 0.90 PPARD (0.48) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL2492189 0.88 PPARD (0.50) PPARDPPARAPPARGFFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014652-B1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR NIPPON CHEMIPHAR CO (JP) 2014-08-06 EP claimed
US-20190255022-A1 WOUND-HEALING AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2019-08-22 US disclosed
EP-3456327-A1 WOUND-HEALING AGENT Nippon Chemiphar Co., Ltd. (JP) 2019-03-20 EP disclosed
EP-2014652-B1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR NIPPON CHEMIPHAR CO (JP) 2014-08-06 EP disclosed
US-20130217734-A1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA NIPPON CHEMIPHAR CO., LTD. (JP) 2013-08-22 US disclosed
US-8404726-B2 Activating agent for peroxisome proliferator activated receptor δ NIPPON CHEMIPHAR CO. LTD. (JP) 2013-03-26 US disclosed
EP-2464349-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES Cerenis Therapeutics S.A. (FR) 2012-06-20 EP disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
US-20110092517-A1 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. 2011-04-21 US disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
US-20090298896-A1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA NIPPON CHEMIPHAR CO. LTD 2009-12-03 US disclosed
EP-2014652-A1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR Nippon Chemiphar Co., Ltd. (JP) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092517-A1 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases PPARD, PPARG, PPARA PPARD 1/4885PPARA 3/4885PPARG 2/4885
US-20090298896-A1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA PPARA, PPARG, PPARD PPARD 3/4885PPARA 1/4885PPARG 2/4885
US-20190255022-A1 WOUND-HEALING AGENT PPARG, PPARA, PPARD PPARD 3/4885PPARA 2/4885PPARG 1/4885
US-20130217734-A1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA PPARA, PPARG, PPARD PPARD 3/4885PPARA 1/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.